Epizyme Stock Price

0.01 (0.94%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 6,842,833
Bid Price 1.05
Ask Price 1.07
News (1)
Day High 1.14


52 Week Range


Day Low 1.04
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Epizyme Inc EPZM NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.01 0.94% 1.07 19:59:32
Open Price Low Price High Price Close Price Prev Close
1.06 1.04 1.14 1.055 1.06
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
25,475 6,842,833 $ 1.08 $ 7,420,786 - 1.015 - 12.10
Last Trade Time Type Quantity Stock Price Currency
19:59:32 formt 840 $ 1.07 USD


Draw Mode:

Epizyme Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 111.17M 103.90M 66.51M $ 15.76M $ - -2.29 -0.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 207.57k 1.40%

more financials information »

Epizyme News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical EPZM Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.172.211.0151.205,783,600-1.10-50.69%
1 Month2.632.751.0151.642,544,125-1.56-59.32%
3 Months4.7755.141.0152.622,209,114-3.71-77.59%
6 Months6.707.011.0153.581,527,552-5.63-84.03%
1 Year11.9012.101.0155.711,314,173-10.83-91.01%
3 Years9.5528.821.01511.211,033,838-8.48-88.8%
5 Years10.0528.821.01511.71848,361-8.98-89.35%

Epizyme Description

Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing and commercializing novel epigenetic medicines. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL), Phase II clinical trial for relapsed or refractory patients with mesothelioma, Phase I dose-escalation and expansion study for children with INI1-negative solid tumors. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias and PRMT5 inhibitor.
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220129 04:11:09